









Markets
/
Stocks
/
nasdaq-inmb
/

INmune Bio Inc

INMB



View Detailed Chart

1.830USD

+0.010+0.55%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

48.65MMarket Cap

LossP/E TTM



INmune Bio Inc

1.830

+0.010+0.55%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.55%

5 Days

-8.96%

1 Month

+22.82%

6 Months

-71.32%

Year to Date

-60.81%

1 Year

-58.41%

View Detailed Chart

TradingKey Stock Score of INmune Bio Inc

Currency: USD Updated: 2025-12-19

Key Insights

INmune Bio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 129/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.40.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

INmune Bio Inc's Score

Industry at a Glance

Industry Ranking

129 / 404

Overall Ranking

250 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.400

Target Price

+311.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

INmune Bio Inc Highlights

StrengthsRisks

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 14.00K.

Overvalued

The company’s latest PE is -0.88, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.76M shares, decreasing 18.86% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 876.29K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.74.